Attenuating role of withaferin A in the proliferation and migration of lung cancer cells via a p53‑miR‑27a/miR‑10b pathway

Lin,Chen-Chu; Yang,Tsung-Ying; Lu,Hseuh-Ju; Wan,Chen-Kai; Hsu,Shih-Lan; Wu,Chun-Chi

doi:10.3892/ol.2021.12493

Attenuating role of withaferin A in the proliferation and migration of lung cancer cells via a p53‑miR‑27a/miR‑10b pathway

Authors:
- Chen-Chu Lin
- Tsung-Ying Yang
- Hseuh-Ju Lu
- Chen-Kai Wan
- Shih-Lan Hsu
- Chun-Chi Wu
View Affiliations

Affiliations: Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan, R.O.C., Department of Internal Medicine, Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan, R.O.C., Department of Internal Medicine, Division of Medical Oncology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan, R.O.C., Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan, R.O.C.
Published online on: January 26, 2021 https://doi.org/10.3892/ol.2021.12493
Article Number: 232

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are known to play a key role in tumorigenesis and usually serve as therapeutic targets in cancer treatment. In the present study, the inhibitory effects and the targeting miRNAs of withaferin A (WA) were investigated in human lung cancer cells. Different lung cancer cell lines were administrated with different concentrations of WA for different time interval followed by western blot or reverse transcription‑quantitative PCR analyses to determine the underlying signaling pathway. The results demonstrated that WA decreased the viability of lung cancer cells in a caspase‑dependent manner. Further investigations indicated that treatment with WA induced the expression of proapoptotic molecules, p53 and Bax, and decreased Bcl‑2 expression in A549 cells. Notably, the results demonstrated that WA also decreased the motility of lung cancer cells in a dose‑dependent manner, at a relatively lower concentration. Western blot analysis revealed increased E‑cadherin and decreased vimentin expression levels in lung cancer cells treated with WA. In addition, two oncomiRs, including miR‑10b and miR‑27a, which regulate the expression of E‑cadherin and Bax, respectively, were downregulated in the presence of WA. The ectopic expression of miR‑10b mimics was able to recover the WA‑decreased motility of lung cancer cells, which was accompanied by a reduction in E‑cadherin expression. Conversely, the ectopic expression of miR‑27a mimics decreased the expression of Bax and recovered the viability of lung cancer cells attenuated by WA. In addition, the ectopic expression of p53‑wild type decreased the expression levels of both miR‑10b and miR‑27a, whereas p53 knockdown induced their expression. Transient knockdown of p53 decreased the inhibitory effects of WA in the motility and viability of lung cancer cells, suggesting an association between WA‑p53‑miR‑10b/27a and motility/viability. Further investigations demonstrated that p53 knockdown in lung cancer stable cell lines exhibited higher levels of both miR‑10b and miR‑27a, and higher motility and viability following treatment with WA. However, suppression of miR‑10b and miR‑27a effectively decreased motility and viability, respectively, following treatment with WA. Taken together, the results of the present study suggest that WA inhibits the functionality of lung cancer cells by decreasing the expression levels of both miR‑10b and miR‑27a in a p53‑dependent manner.

View Figures

View References

1	Islami F, Torre LA and Jemal A: Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 4:3272015.PubMed/NCBI
2	Lin HT, Liu FC, Wu CY, Kuo CF, Lan WC and Yu HP: Epidemiology and survival outcomes of lung cancer: A population-based study. Biomed Res Int. 2019:81481562019. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
4	Schabath MB and Cote ML: Cancer progress and priorities: Lung cancer. Cancer Epidemiol Biomarkers Prev. 28:1563–1579. 2019. View Article : Google Scholar : PubMed/NCBI
5	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
6	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
7	Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, Zhao S, Sun X, Cui L, Pan L and Liu S: MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget. 7:84508–84519. 2016. View Article : Google Scholar : PubMed/NCBI
8	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
9	Hu Y, Qiu Y, Yagüe E, Ji W, Liu J and Zhang J: miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 7:e22912016. View Article : Google Scholar : PubMed/NCBI
10	Mraz M, Malinova K, Mayer J and Pospisilova S: MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun. 390:1–4. 2009. View Article : Google Scholar : PubMed/NCBI
11	Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, Tomsits P, Hildebrand B, Kääb S, Wakili R, et al: Stability of circulating blood-based microRNAs-pre-analytic methodological considerations. PLoS One. 12:e01679692017. View Article : Google Scholar : PubMed/NCBI
12	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:2032017. View Article : Google Scholar : PubMed/NCBI
13	Bajan S and Hutvagner G: RNA-based therapeutics: From antisense oligonucleotides to miRNAs. Cells. 9:1372020. View Article : Google Scholar
14	Fabbri M: MicroRNAs and cancer: Towards a personalized medicine. Curr Mol Med. 13:751–756. 2013. View Article : Google Scholar : PubMed/NCBI
15	Florczuk M, Szpechcinski A and Chorostowska-Wynimko J: miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: Current perspectives. Target Oncol. 12:179–200. 2017. View Article : Google Scholar : PubMed/NCBI
16	Rayan A, Raiyn J and Falah M: Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS One. 12:e01879252017. View Article : Google Scholar : PubMed/NCBI
17	Sharifi-Rad J, Ozleyen A, Boyunegmez Tumer T, Oluwaseun Adetunji C, El Omari N, Balahbib A, Taheri Y, Bouyahya A, Martorell M, Martins N and Cho WC: Natural products and synthetic analogs as a source of antitumor drugs. Biomolecules. 9:6792019. View Article : Google Scholar
18	Yu SM and Kim SJ: Production of reactive oxygen species by withaferin A causes loss of type collagen expression and COX-2 expression through the PI3K/Akt, p38, and JNK pathways in rabbit articular chondrocytes. Exp Cell Res. 319:2822–2834. 2013. View Article : Google Scholar : PubMed/NCBI
19	Roy RV, Suman S, Das TP, Luevano JE and Damodaran C: Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. J Nat Prod. 76:1909–1915. 2013. View Article : Google Scholar : PubMed/NCBI
20	Stan SD, Zeng Y and Singh SV: Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer. 60 (Suppl 1):S51–S60. 2008. View Article : Google Scholar
21	Mayola E, Gallerne C, Degli Esposti D, Esposti DD, Martel C, Pervaiz S, Larue L, Debuire B, Lemoine A, Brenner C and Lemaire C: Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis. 16:1014–1027. 2011. View Article : Google Scholar : PubMed/NCBI
22	Fong MY, Jin S, Rane M, Singh RK, Gupta R and Kakar SS: Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One. 7:e422652012. View Article : Google Scholar : PubMed/NCBI
23	Cai Y, Sheng ZY, Chen Y and Bai C: Effect of withaferin A on A549 cellular proliferation and apoptosis in non-small cell lung cancer. Asian Pac J Cancer Prev. 15:1711–1714. 2014. View Article : Google Scholar : PubMed/NCBI
24	Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, Lee JM, Kim YH, Park JW and Kwon TK: Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis. 13:1494–1504. 2008. View Article : Google Scholar : PubMed/NCBI
25	Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AA, Zhan CG and Sun D: Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol. 79:542–551. 2010. View Article : Google Scholar : PubMed/NCBI
26	Hahm ER, Lee J, Huang Y and Singh SV: Withaferin a suppresses estrogen receptor-α expression in human breast cancer cells. Mol Carcinog. 50:614–624. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kyakulaga AH, Aqil F, Munagala R and Gupta RC: Withaferin a inhibits epithelial to mesenchymal transition in non-small cell lung cancer cells. Sci Rep. 8:157372018. View Article : Google Scholar : PubMed/NCBI
28	Grogan PT, Sleder KD, Samadi AK, Zhang H, Timmermann BN and Cohen MS: Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways. Invest New Drugs. 31:545–557. 2013. View Article : Google Scholar : PubMed/NCBI
29	Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, et al: Identification of withaferin A as a potential candidate for anti-cancer therapy in non-small cell lung cancer. Cancers (Basel). 11:10032019. View Article : Google Scholar
30	Strober W: Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 21:A. 3B. 1–A. 3B. 2. 1997.
31	Ernst O and Zor T: Linearization of the Bradford protein assay. J Vis Exp. 19182010.
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Wu CC, Huang KF, Yang TY, Li YL, Wen CL, Hsu SL and Chen TH: The topoisomerase 1 inhibitor austrobailignan-1 isolated from Koelreuteria Henryi induces a G2/M-phase arrest and cell death independently of p53 in non-small cell lung cancer cells. PLoS One. 10:e01320522015. View Article : Google Scholar : PubMed/NCBI
34	Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP and Looi CY: The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells. 8:11182019. View Article : Google Scholar
35	Liang G, Ding M, Lu H, Cao NA, Niu Y, Gao Y and Lu J: Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncol Lett. 10:1527–1532. 2015. View Article : Google Scholar : PubMed/NCBI
36	Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA: Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
37	Zhang R, He Y, Zhang X, Xing B, Sheng Y, Lu H and Wei Z: Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett. 314:155–165. 2012. View Article : Google Scholar : PubMed/NCBI
38	Oh JH and Kwon TK: Withaferin A inhibits tumor necrosis factor-α-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol. 9:614–619. 2009. View Article : Google Scholar : PubMed/NCBI
39	Zhou YF, Yu XT, Yao JJ, Xu CW, Huang JH, Wan Y and Wu MJ: Withaferin A inhibits hepatoma cell proliferation through induction of apoptosis and cell cycle arrest. Int J Clin Exp Pathol. 9:12381–12389. 2016.
40	Chang HW, Li RN, Wang HR, Liu JR, Tang JY, Huang HW, Chan YH and Yen CY: Withaferin A induces oxidative stress-mediated apoptosis and DNA damage in oral cancer cells. Front Physiol. 8:6342017. View Article : Google Scholar : PubMed/NCBI
41	Lv TZ and Wang GS: Antiproliferation potential of withaferin A on human osteosarcoma cells via the inhibition of G2/M checkpoint proteins. Exp Therap Med. 10:323–329. 2015. View Article : Google Scholar
42	Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, Harvey RD, Garcia A and Marcus AI: Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer. 129:2744–2755. 2011. View Article : Google Scholar : PubMed/NCBI
43	Mello SS and Attardi LD: Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 51:65–72. 2018. View Article : Google Scholar : PubMed/NCBI
44	Braithwaite A and Prives C: p53: More research and more questions. Cell Death Differ. 13:877–880. 2006. View Article : Google Scholar : PubMed/NCBI
45	Wu M, Ye H, Tang Z, Shao C, Lu G, Chen B, Yang Y, Wang G and Hao H: p53 dynamics orchestrates with binding affinity to target genes for cell fate decision. Cell Death Dis. 8:e31302017. View Article : Google Scholar : PubMed/NCBI
46	Yang TY, Teng CLJ, Lin TCC, Chen KC, Hsu SL and Wu CC: Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a. Int J Cancer. 142:92–108. 2018. View Article : Google Scholar : PubMed/NCBI
47	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
48	Lu C and El-Deiry WS: Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis. 14:597–606. 2009. View Article : Google Scholar : PubMed/NCBI
49	He C, Li L, Guan X, Xiong L and Miao X: Mutant p53 gain of function and chemoresistance: The role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 62:43–53. 2017. View Article : Google Scholar : PubMed/NCBI
50	Sheedy P and Medarova Z: The fundamental role of miR-10b in metastatic cancer. Am J Cancer Res. 8:1674–1688. 2018.PubMed/NCBI
51	Li X, Xu M, Ding L and Tang J: MiR-27a: A novel biomarker and potential therapeutic target in tumors. J Cancer. 10:2836–2848. 2019. View Article : Google Scholar : PubMed/NCBI
52	Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, Lobie PE and Zhu T: c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem. 288:18121–18133. 2013. View Article : Google Scholar : PubMed/NCBI
53	Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
54	Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD: p53: A frequent target for genetic abnormalities in lung cancer. Science. 246:491–494. 1989. View Article : Google Scholar : PubMed/NCBI